Tag: Lung cancer
-
Clinical Phases of Drug Development: Dostarlimab combination facilitates promising lung cancer survival.
The Phase II trial of the PD-1 inhibitors for non-squamous non-small cell lung cancer suggested that there are chances of getting a positive outcome with the survival rates of the lung cancer patients.